Literature DB >> 11582878

[Co-infections of leishmania/HIV in south Europe].

P Desjeux1, B Piot, K O'Neill, J P Meert.   

Abstract

The Leishmania/HIV co-infection has emerged as a result of the increasing overlap between leishmaniasis (mainly visceral, more rarely cutaneous) and AIDS, which is due to the spread of the AIDS pandemic to rural areas and that of visceral leishmaniasis to suburban areas. Cases of co-infection have so far been reported from 33 countries around the world, most of the cases have been notified in south-western Europe. 1,627 cases have been notified from Spain, France, Italy and Portugal. While Leishmania/HIV co-infection is increasing in eastern Africa, cases of co-infection are expected to diminish in South-western Europe due to the new highly active anti-retroviral therapy (HAART). In 1998, a world wide WHO/UNAIDS surveillance network was established, which now includes 28 member institutions. In south-western Europe, the surveillance system based on 16 institutions is now well established. The systematic use of standardized and recently computerized case-report forms, the central international registry at WHO headquarters, and finally the use of a geographic information system (GIS) for mapping and monitoring co-infections have improved the overall quality of epidemiological data gathering. All member institutions of the network report to WHO on an annual basis. World wide information is analysed and periodically disseminated through international publications. The GIS integrates epidemiological and demographic data sets and allows for the mapping of co-infection cases down to locality level. The system can be used to easily visualise and analyse the spatial distribution of co-infection cases and to permit monitoring of the evolution of the distribution of the cases over time. The risk of co-infected patients, as carriers of Leishmania in the blood, to be a source of infection for the sandfly, has been recently confirmed. Moreover intravenous drug users also transmit the disease through the sharing of needles.

Entities:  

Mesh:

Year:  2001        PMID: 11582878

Source DB:  PubMed          Journal:  Med Trop (Mars)        ISSN: 0025-682X


  9 in total

Review 1.  The genetics of Leishmania virulence.

Authors:  Eugenia Bifeld; Joachim Clos
Journal:  Med Microbiol Immunol       Date:  2015-06-06       Impact factor: 3.402

2.  16alpha-Hydroxycleroda-3,13 (14)Z-dien-15,16-olide from Polyalthia longifolia: a safe and orally active antileishmanial agent.

Authors:  Pragya Misra; Koneni V Sashidhara; Suriya Pratap Singh; Awanish Kumar; Reema Gupta; Shailendra S Chaudhaery; Souvik Sen Gupta; H K Majumder; Anil K Saxena; Anuradha Dube
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

3.  Role of the domestic dog as a reservoir host of Leishmania donovani in eastern Sudan.

Authors:  Mo'awia M Hassan; Omran F Osman; Fathi Ma El-Raba'a; Henk Dfh Schallig; Dia-Eldin A Elnaiem
Journal:  Parasit Vectors       Date:  2009-06-17       Impact factor: 3.876

4.  Cloning of S-adenosyl-L-methionine:C-24-Delta-sterol-methyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-Resistant promastigotes.

Authors:  Mohammad Pourshafie; Stanislas Morand; Alain Virion; Michaelle Rakotomanga; Corinne Dupuy; Philippe M Loiseau
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

5.  Identification of leishmania isolates from healing and nonhealing cutaneous leishmaniasis patients using internal transcribed spacer region PCR.

Authors:  Sepideh Tolouei; Seyed Hossein Hejazi; Kamran Ghaedi; Seyed Javad Hasheminia
Journal:  Jundishapur J Microbiol       Date:  2014-04-01       Impact factor: 0.747

6.  IL12 p35 and p40 subunit genes administered as pPAL plasmid constructs do not improve protection of pPAL-LACK vaccine against canine leishmaniasis.

Authors:  Pedro J Alcolea; Ana Alonso; Adriana Esteban; Paz Peris; Alberto Cortés; Juan A Castillo; Vicente Larraga
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

7.  Risk mapping of human HIV-Leishmaniasis co-infection in Morocco.

Authors:  M Daoudi; S Boussaa; M Echchakery; A Boumezzough
Journal:  Heliyon       Date:  2019-09-12

8.  Leishmania infantum UBC1 in Metacyclic Promastigotes from Phlebotomus perniciosus, a Vaccine Candidate for Zoonotic Visceral Leishmaniasis.

Authors:  Jaime Larraga; Pedro J Alcolea; Ana M Alonso; Luis T C Martins; Inmaculada Moreno; Mercedes Domínguez; Vicente Larraga
Journal:  Vaccines (Basel)       Date:  2022-02-03

9.  Efficient one-pot synthesis, molecular docking and in silico ADME prediction of bis-(4-hydroxycoumarin-3-yl) methane derivatives as antileishmanial agents.

Authors:  Zahid Zaheer; Firoz A Kalam Khan; Jaiprakash N Sangshetti; Rajendra H Patil
Journal:  EXCLI J       Date:  2015-08-10       Impact factor: 4.068

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.